The efficacy of lafutidine for nab-paclitaxel-induced peripheral neuropathy

The efficacy of lafutidine for nab-paclitaxel-induced peripheral neuropathy - The efficacy of lafutidine for nab-paclitaxel-induced peripheral neuropathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011301

Enrollment

Registered

2013-07-29

Start date

2013-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Lafutidine is administered orally at the dose of 10 mg twice daily for 9 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)breast cancer patient who are planning to chemotherapy using nab-paclitaxel 2)Cases it is considered to be performed to continue treatment with nab-paclitaxel 4 weeks or more 3)age: >=20 and =<75 4)peripheral neuropathy is not expressed 5)expected more than 6 months survival 6)written informed consent

Exclusion criteria

Exclusion criteria: 1)with severe complications (such as liver failure, renal failure, heart failure) 2)with history of allergy 3)case of taking pregabalin 4)doctor's decision not to be registered to this study

Design outcomes

Primary

Measure	Time frame
Patient Neurotixicity Questionnaire(PNQ) and CTCAE v4.0	—

Secondary

Measure	Time frame
adverse event	—

Countries

Japan

Contacts

Public ContactSadatoshi SUGAE

Yokohama City University Hospital Gastroenterological surgery

sugae@f7.dion.ne.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026